Monte Rosa Therapeutics, Inc. GLUE Proceeds From Issuance Of Warrants
Proceeds From Issuance Of Warrants at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfWarrants.
The official record: Monte Rosa Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s proceeds from issuance of warrants.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s proceeds from issuance of warrants?
- Monte Rosa Therapeutics, Inc. (GLUE) reported proceeds from issuance of warrants of $0 in Q4 2025.
- How has Monte Rosa Therapeutics, Inc.'s proceeds from issuance of warrants changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s proceeds from issuance of warrants decreased by 100.0% year-over-year, from $12.5M to $0.
- What does proceeds from issuance of warrants mean?
- This reflects the cash inflows generated from the sale or exercise of warrants, which grant holders the right to purchase company shares at a specified price. It serves as a source of non-dilutive or secondary capital that can bolster the balance sheet. Analyzing this helps investors understand alternative financing strategies and potential future dilution impacts on existing shareholders.